Back to Search Start Over

Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity

Authors :
Giulia Bianchini
Bernhard Ellinger
Lucio H. Freitas-Junior
Giulia Fiorani
Eulogio López-Montero
Maria Laura Bolognesi
Maria Teresa Molina
Gesa Witt
Elisa Uliassi
R. Luise Krauth-Siegel
Maria Paola Costi
Romana Fato
Christian Bergamini
Federico Falchi
Sheraz Gul
J. Carlos Menéndez
Carolina B. Moraes
Maria Kuzikov
Andrea Cavalli
Chiara Borsari
DIPARTIMENTO DI FARMACIA E BIOTECNOLOGIE
Facolta' di MEDICINA e CHIRURGIA
AREA MIN. 03 - Scienze chimiche
AREA MIN. 05 - Scienze biologiche
Publica
Uliassi, Elisa
Fiorani, Giulia
Krauth-Siegel, R. Luise
Bergamini, Christian
Fato, Romana
Bianchini, Giulia
Carlos Menéndez, J.
Molina, Maria Teresa
López-Montero, Eulogio
Falchi, Federico
Cavalli, Andrea
Gul, Sheraz
Kuzikov, Maria
Ellinger, Bernhard
Witt, Gesa
Moraes, Carolina B.
Freitas-Junior, Lucio H.
Borsari, Chiara
Costi, Maria Paola
Bolognesi, Maria Laura
Publication Year :
2017

Abstract

none 20 si Crassiflorone is a natural product with anti-mycobacterial and anti-gonorrhoeal properties, isolated from the stem bark of the African ebony tree Diospyros crassiflora. We noticed that its pentacyclic core possesses structural resemblance to the quinone-coumarin hybrid 3, which we reported to exhibit a dual-targeted inhibitory profile towards Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR). Following this basic idea, we synthesized a small library of crassiflorone derivatives 15-23 and investigated their potential as anti-trypanosomatid agents. 19 is the only compound of the series showing a balanced dual profile at 10 μM (% inhibitionTbGAPDH= 64% and % inhibitionTcTR= 65%). In phenotypic assay, the most active compounds were 18 and 21, which at 5 μM inhibited Tb bloodstream-form growth by 29% and 38%, respectively. Notably, all the newly synthesized compounds at 10 μM did not affect viability and the status of mitochondria in human A549 and 786-O cell lines, respectively. However, further optimization that addresses metabolic liabilities including solubility, as well as cytochromes P450 (CYP1A2, CYP2C9, CYP2C19, and CYP2D6) inhibition, is required before this class of natural product-derived compounds can be further progressed. Uliassi, Elisa; Fiorani, Giulia; Krauth-Siegel, R. Luise; Bergamini, Christian; Fato, Romana; Bianchini, Giulia; Carlos Menéndez, J.; Molina, Maria Teresa; López-Montero, Eulogio; Falchi, Federico; Cavalli, Andrea; Gul, Sheraz; Kuzikov, Maria; Ellinger, Bernhard; Witt, Gesa; Moraes, Carolina B.; Freitas-Junior, Lucio H.; Borsari, Chiara; Costi, Maria Paola; Bolognesi, Maria Laura* Uliassi, Elisa; Fiorani, Giulia; Krauth-Siegel, R. Luise; Bergamini, Christian; Fato, Romana; Bianchini, Giulia; Carlos Menéndez, J.; Molina, Maria Teresa; López-Montero, Eulogio; Falchi, Federico; Cavalli, Andrea; Gul, Sheraz; Kuzikov, Maria; Ellinger, Bernhard; Witt, Gesa; Moraes, Carolina B.; Freitas-Junior, Lucio H.; Borsari, Chiara; Costi, Maria Paola; Bolognesi, Maria Laura*

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....bd27927f3e2d6ad95ba8f890079d66db